Kovitz Investment Group Partners, LLC Savara Inc Transaction History
Kovitz Investment Group Partners, LLC
- $28.6 Billion
- Q4 2024
A detailed history of Kovitz Investment Group Partners, LLC transactions in Savara Inc stock. As of the latest transaction made, Kovitz Investment Group Partners, LLC holds 25,214 shares of SVRA stock, worth $71,859. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,214
Previous 25,214
-0.0%
Holding current value
$71,859
Previous $77,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SVRA
# of Institutions
140Shares Held
153MCall Options Held
55.6KPut Options Held
600-
Nea Management Company, LLC Timonium, MD24.5MShares$69.7 Million5.37% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$41.5 Million12.07% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$35.2 Million6.2% of portfolio
-
Vestal Point Capital, LP New York, NY10.8MShares$30.7 Million1.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.66MShares$24.7 Million1.59% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $325M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.